Get the Stockscreener App
25.79
2.10%
0.53
Zymeworks Bc Inc stock is traded at $25.79, with a volume of 486.98K.
It is up +2.10% in the last 24 hours and down -5.01% over the past month.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
See More
Previous Close:
$25.26
Open:
$25.28
24h Volume:
486.98K
Relative Volume:
0.43
Market Cap:
$1.85B
Revenue:
$81.26M
Net Income/Loss:
$-102.66M
P/E Ratio:
-18.86
EPS:
-1.3678
Net Cash Flow:
$-77.62M
1W Performance:
+2.54%
1M Performance:
-5.01%
6M Performance:
-5.70%
1Y Performance:
+52.42%
1-Day Range:
$25.28
$26.34
1-Week Range:
$25.00
$27.02
52-Week Range:
$16.00
$31.34
Zymeworks Bc Inc Stock (ZYME) Company Profile
Name
Zymeworks Bc Inc
Sector
Industry
Phone
302-274-8744
Address
108 PATRIOT DRIVE, SUITE A, MIDDLETOWN
Compare ZYME vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Bc Inc
|
25.79 | 1.85B | 81.26M | -102.66M | -77.62M | -1.3678 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zymeworks Bc Inc Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-29-26 | Initiated | TD Cowen | Buy |
| Sep-17-26 | Initiated | Wolfe Research | Outperform |
| Aug-26-26 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-26 | Resumed | Truist | Buy |
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-24-25 | Resumed | Wells Fargo | Equal Weight |
| Oct-14-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Bc Inc Stock (ZYME) Latest News
Jefferies keeps Buy on Zymeworks stock at USD 50 target - AD HOC NEWS
Zymeworks stock fell 2.14 percent as 2026 guidance reset - AD HOC NEWS
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook - TradingView
EBIT per share of Zymeworks Inc. – HAN:ZA8 - TradingView
CapEx per share of Zymeworks Inc. – HAN:ZA8 - TradingView
Taxes of Zymeworks Inc. – HAN:ZA8 - TradingView
Zymeworks stock coverage reinstated at Buy by TD Cowen on acquisition - Investing.com Nigeria
Citigroup keeps 'Buy' on Zymeworks after acquis... - Pluang
Zymeworks stock coverage reinstated at Buy by TD Cowen on acquisition - Investing.com Canada
Dilution adjustment of Zymeworks Inc. – HAN:ZA8 - TradingView
Zymeworks Inc. (ZYME) stock price, news, quote and history - Yahoo Finance UK
Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Eyes Growth in COPD Market - GuruFocus
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal - TradingView
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal - Benzinga
Zymeworks Completes Theravance Acquisition Deal - grafa.com
Zymeworks Inc. Updates Earnings Guidance for the Year 2026 - marketscreener.com
Zymeworks Inc. Updates Earnings Guidance for the Year 2026 - marketscreener.com
Zymeworks Inc. (ZYME) Theravance Biopharma, Inc.M&A CallSlideshow (NASDAQ:ZYME) 2026-09-28 - Seeking Alpha
Zymeworks Inc. and Theravance Biopharma, Inc. Acquisition Call Transcript - GuruFocus
Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Int - GuruFocus
Zymeworks Inc Expects Total Revenue, Including Collaboration Revenue From Yupelri, For 2026 To Be Between $278 Million And $292 Million - TradingView
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition - GlobeNewswire Inc.
Zymeworks Announces Updated 2026 Financial Guidance and - GlobeNewswire
Bank of America Corp DE Buys 219,071 Shares of Zymeworks Inc. $ZYME - MarketBeat
Vancouver biotech Zymeworks closes US$929M Theravance deal - Business in Vancouver
A $350 million debt issue helped fund Zymeworks (ZYME)'s Theravance acquisition, with cash due per eligible share. - Stock Titan
Zymeworks Completes Acquisition of Theravance Biopharma - GlobeNewswire
Squarepoint Ops LLC Reduces Holdings in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow (NASDAQ:ZYME) - Seeking Alpha
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 238,026 Shares of Zymeworks Inc. $ZYME - MarketBeat
Wellington Management Group LLP Takes $2.88 Million Position in Zymeworks Inc. $ZYME - MarketBeat
Legal & General Group Plc Makes New $1.13 Million Investment in Zymeworks Inc. $ZYME - MarketBeat
Bank of New York Mellon Corp Acquires New Holdings in Zymeworks Inc. $ZYME - MarketBeat
JPMorgan Chase & Co. Boosts Zymeworks (NASDAQ:ZYME) Price Target to $33.00 - MarketBeat
Zymeworks (NASDAQ:ZYME) Hits New 1-Year HighTime to Buy? - MarketBeat
Zymeworks stock hits 52-week high at 30.75 USD - Investing.com
Zymeworks stock hits 52-week high at 30.75 USD By Investing.com - Investing.com Nigeria
Zymeworks stock hits 52-week high at 30.75 USD By Investing.com - Investing.com Canada
Zymeworks stock hits 52-week high at 30.75 USD By Investing.com - Investing.com India
ZJM stock holds near its latest trade. Zymeworks data still drives the setup - ad-hoc-news.de
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer - FinancialContent
Enterprise value to revenue forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView
Man Group plc Invests $5.51 Million in Zymeworks Inc. $ZYME - marketbeat.com
4,251,030 Shares in Zymeworks Inc. $ZYME Bought by BlackRock Inc. - marketbeat.com
Zymeworks stock holds near $28.27 as market cap tops $2.01 billion - ad-hoc-news.de
FY2026 EPS Estimates for Zymeworks Raised by HC Wainwright - MarketBeat
Zymeworks (ZYME), What Is Behind The Renewed Attention? - Yahoo Finance
Zymeworks shifts to revenue growth after FDA ap... - Pluang
HC Wainwright Has Strong Estimate for Zymeworks Q3 Earnings - marketbeat.com
Zymeworks moves higher as Street cheers Ziihera regimen approval - Seeking Alpha
Zymeworks Bc Inc Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zymeworks Bc Inc Stock (ZYME) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jeffrey T L Smith | Former Officer |
Mar 06 '26 |
Proposed Sale |
24.80 |
247,333 |
6,133,858 |
0 |
| Leone D Patterson | Former officer |
Feb 17 '26 |
Proposed Sale |
22.60 |
31,641 |
715,087 |
0 |
| Leone D Patterson | Former officer |
Feb 13 '26 |
Proposed Sale |
23.17 |
128,548 |
2,978,457 |
0 |
| Mark Hollywood | Officer |
Jan 12 '26 |
Proposed Sale |
23.17 |
6,120 |
141,800 |
0 |
| Kenneth Galbraith | Officer |
Jan 12 '26 |
Proposed Sale |
23.17 |
30,424 |
704,924 |
0 |
| Paul Andrew Moore | Officer |
Jan 12 '26 |
Proposed Sale |
23.17 |
9,560 |
221,505 |
0 |
| Jeffrey T L Smith | Officer |
Jan 12 '26 |
Proposed Sale |
23.17 |
9,310 |
215,713 |
0 |
| Hollywood Mark | EVP & Chief Operating Officer |
Jan 12 '26 |
Option Exercise |
0.00 |
17,666 |
0 |
139,033 |
| Hollywood Mark | EVP & Chief Operating Officer |
Jan 12 '26 |
Sale |
22.67 |
6,120 |
138,762 |
132,913 |
| Smith Jeffrey T L | EVP & Chief Medical Officer |
Jan 12 '26 |
Option Exercise |
0.00 |
17,666 |
0 |
36,018 |
3.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):